Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

473 questions in 36 reviews · HIV/AIDS

current versions

No studies 38 · 8%Ungraded 9 · 1.9%Very low 126 · 26.6%Low 127 · 26.8%Moderate 152 · 32.1%High 21 · 4.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Adjunctive corticosteroids vs no such treatment Death at 1 month (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection (2015) · Cochrane	RR 0.56 [0.32, 0.98]	6 studies · 489 participants	High
Adjunctive corticosteroids vs no such treatment Death at 3 to 4 months (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection (2015) · Cochrane	RR 0.59 [0.41, 0.85]	5 studies · 448 participants	High
Adjunctive corticosteroids vs no such treatment Death in hospital; children · patients with Pneumocystis jiroveci pneumonia and HIV infection Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection (2015) · Cochrane	RR 0.81 [0.51, 1.29]	1 study · 100 participants	Moderate
Adjunctive corticosteroids vs no such treatment Need for mechanical ventilation at 1 month · patients with Pneumocystis jiroveci pneumonia and HIV infection Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection (2015) · Cochrane	RR 0.38 [0.2, 0.73]	3 studies · 388 participants	Moderate
HAART + ABV vs HAART alone Mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.92 [0.45, 1.88]	1 study · 100 participants	Moderate
HAART + liposomal anthracycline vs HAART alone Kaposi's sarcoma IRIS · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.49 [0.16, 1.55]	1 study · 129 participants	Moderate
HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 1.04 [0.07, 15.73]	1 study · 49 participants	Moderate
HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 2.08 [0.2, 21.5]	1 study · 49 participants	Moderate
HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin Clinical response ‐ partial response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 1.04 [0.5, 2.17]	1 study · 49 participants	Moderate
HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.63 [0.27, 1.45]	1 study · 49 participants	Moderate
HAART + pegylated liposomal doxorubicin vs HAART + liposomal daunorubicin Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	no estimate extracted	1 study · 46 participants	Moderate
Liposomal daunorubicin vs ABV Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.78 [0.34, 1.82]	1 study · 227 participants	Moderate
Liposomal daunorubicin vs ABV Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 2.87 [0.3, 27.19]	1 study · 227 participants	Moderate
Liposomal daunorubicin vs ABV Clinical response ‐ partial response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.83 [0.53, 1.31]	1 study · 227 participants	Moderate
Liposomal daunorubicin vs ABV Clinical response ‐ overall response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.9 [0.58, 1.38]	1 study · 227 participants	Moderate
HAART + ABV vs HAART alone Progressive disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.1 [0.01, 0.75]	1 study · 100 participants	Moderate
Liposomal daunorubicin vs ABV Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 1.08 [0.87, 1.33]	1 study · 227 participants	Moderate
Liposomal daunorubicin vs ABV Adverse events · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 1.01 [0.96, 1.06]	1 study · 227 participants	Moderate
Oral etoposide vs ABV Mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 1.08 [0.98, 1.19]	1 study · 178 participants	Moderate
Bleomycin vs ABV Mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 1.09 [0.87, 1.36]	1 study · 24 participants	Very low
Bleomycin vs ABV Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	no estimate extracted	1 study · 24 participants	Very low
Bleomycin vs ABV Clinical response ‐ partial response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.11 [0.01, 1.86]	1 study · 24 participants	Very low
Bleomycin vs ABV Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.88 [0.47, 1.63]	1 study · 24 participants	Very low
Bleomycin vs ABV Clinical response ‐ progression · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 11 [0.67, 179.29]	1 study · 24 participants	Very low
Bleomycin vs ABV Adverse events · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 11 [0.67, 179.29]	1 study · 24 participants	Very low
Liposomal doxorubicin vs conservative management Mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.93 [0.75, 1.15]	1 study · 29 participants	Moderate
HAART + ABV vs HAART alone Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 2 [0.64, 6.22]	1 study · 100 participants	Moderate
HAART + ABV vs HAART alone Clinical response ‐ partial response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 1.71 [1.01, 2.91]	1 study · 100 participants	Moderate
HAART + ABV vs HAART alone Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.06 [0, 0.99]	1 study · 100 participants	Moderate
HAART + ABV vs HAART alone Clinical response ‐ overall response (complete and partial) · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 1.78 [1.16, 2.72]	1 study · 100 participants	Moderate
HAART + ABV vs HAART alone Adverse events · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.88 [0.59, 1.32]	1 study · 100 participants	Moderate
HAART + pegylated liposomal doxorubicin vs HAART alone Clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 9 [0.61, 133.08]	1 study · 10 participants	Moderate
HAART + liposomal anthracycline vs HAART alone Mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 1.23 [0.35, 4.38]	1 study · 129 participants	Moderate
Structural and community‐level interventions for increasing condom use vs standard care HIV incidence (person/years) · low and high‐risk populations Structural and community‐level interventions for increasing condom use to prevent the transmission of HIV… (2014) · Cochrane	RR 0.9 [0.69, 1.19]	4 studies · 14279 participants	Moderate
Structural and community‐level interventions for increasing condom use vs standard care HIV prevalence · low and high‐risk populations Structural and community‐level interventions for increasing condom use to prevent the transmission of HIV… (2014) · Cochrane	RR 1.02 [0.79, 1.32]	3 studies · 9042 participants	Low
Structural and community‐level interventions for increasing condom use vs standard care Herpes Simplex Virus 2 (HSV‐2) incidence (person/years) · low and high‐risk populations Structural and community‐level interventions for increasing condom use to prevent the transmission of HIV… (2014) · Cochrane	RR 0.76 [0.55, 1.04]	2 studies · 3877 participants	Moderate
Structural and community‐level interventions for increasing condom use vs standard care HSV‐2 prevalence · low and high‐risk populations Structural and community‐level interventions for increasing condom use to prevent the transmission of HIV… (2014) · Cochrane	RR 1.01 [0.85, 1.2]	2 studies · 2974 participants	Moderate
Structural and community‐level interventions for increasing condom use vs standard care Two or more sexual partners in last year · low and high‐risk populations Structural and community‐level interventions for increasing condom use to prevent the transmission of HIV… (2014) · Cochrane	RR 0.9 [0.78, 1.04]	5 studies · 4008 participants	Moderate
Structural and community‐level interventions for increasing condom use vs standard care Use of condom during last sexual intercourse · low and high‐risk populations Structural and community‐level interventions for increasing condom use to prevent the transmission of HIV… (2014) · Cochrane	RR 1.2 [1.03, 1.4]	3 studies · 1898 participants	Moderate
Structural and community‐level interventions for increasing condom use vs standard care Knowledge: condom can prevent STIs · low and high‐risk populations Structural and community‐level interventions for increasing condom use to prevent the transmission of HIV… (2014) · Cochrane	RR 1.23 [1.07, 1.41]	3 studies · 1231 participants	Moderate
Doctor vs nurse or clinical officer Death (RCTs) · HIV‐infected patients Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.96 [0.82, 1.12]	1 study · 2770 participants	High
Doctor vs nurse or clinical officer Lost to · HIV infected patients on antiretroviral therapy Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.34 [0.18, 0.66]	1 study · 2772 participants	Very low
Doctor vs nurse or clinical officer Death or loss to · HIV infected patients on antiretroviral therapy Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 1.1 [0.86, 1.41]	2 studies · 4332 participants	Moderate
Doctor vs nurse or clinical officer Death or loss to · HIV infected patients on antiretroviral therapy Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.3 [0.17, 0.54]	1 study · 2772 participants	Very low
Doctor vs community health worker Outcomes2 · HIV infected patients on antiretroviral therapy. Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	no estimate extracted	NR	No studies
Doctor vs community health worker Death (RCTs) · HIV infected patients on antiretroviral therapy. Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 1 [0.62, 1.62]	1 study · 559 participants	Moderate
Doctor vs community health worker Lost to · HIV infected patients on antiretroviral therapy. Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.52 [0.12, 2.3]	1 study · 559 participants	Moderate
Doctor vs community health worker Death or lost to · HIV infected patients on antiretroviral therapy. Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.93 [0.6, 1.46]	1 study · 559 participants	Moderate
Doctor vs nurse or clinical officer Death (Cohorts) · HIV‐infected patients Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 1.23 [1.14, 1.33]	2 studies · 39160 participants	Low
Doctor vs nurse or clinical officer Lost to · HIV‐infected patients Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.73 [0.55, 0.97]	1 study · 2770 participants	Moderate